GLP-1R agonist therapy for diabetes: benefits and potential risks
The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: Glucagon-like peptide 1 receptor (GLP-1R) agonists provide good glycemic control combined with low hypoglycemia risk and weight loss. Here, we summarize the recently published data for this therapy class, focusing on sustainability of action, use in combination with basal insulin, and the efficacy of longer acting agents currently in development. The safety profile of GLP-1R agonists is also examined. RECENT FINDINGS: GLP-1R agonists provide sustained efficacy and their combination with basal insulin is well tolerated, providing additional glycemic control and weight benefits compared with basal insulin alone. Data suggest that the convenience of longer acting agents may be at the expense of efficacy. Despite the initial concerns, most evidence indicates that GLP-1R agonists do not increase the risk of pancreatitis or thyroid cancer. However, the extremely low incidence of these events means further investigations are required before a causal link can be eliminated. Large-scale clinical trials investigating the long-term cardiovascular safety of this therapy class are ongoing and may also provide important insights into pancreatic and thyroid safety. SUMMARY: GLP-1R agonists offer sustained glycemic efficacy, weight loss benefits, and a low risk of hypoglycemia. The results of ongoing trials should help to clarify the safety of this therapy class.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Like any medication, GLP-1RAs may have side effects, including nausea, vomiting, diarrhea, and injection site reactions. These side effects are often mild and tend to improve over time.72–74”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [73]
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 2×
“GLP-1R agonists carry a low risk of hypoglycemia because of the glucose-dependent nature of their activity, although this risk is increased in patients receiving concomitant sulfonylurea or insulin [4].”
BackgroundGlucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 5×
“A1C data from clinical trials of GLP-1R agonists approved for use in patients with type 2 diabetes Study ID, name and reference Investigational product (background therapy in all arms) Trial duration (weeks) Change in A1C from baseline Comparator Change in A1C from baseline P value for difference Clinical trials of ap…”
BackgroundInfluentialPancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 1×
“demonstrated an increased risk of pancreatitis with exenatide and the DPP-4 inhibitor sitagliptin [48]; however, it has been criticized for weaknesses in the methodology, including the inherent reporting bias in the source data, problems associated with diagnostic definitions and lack of analysis of confounding factor…”
BackgroundNikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 1×
“Published data also suggests that GLP-1 potentially could provide cardioprotective benefits and enhance cardiovascular function, encouraging further scientific and clinical exploration [6,7].”
BackgroundPlasma Insulin Response to Oral and Intravenous Glucose Administration1
ELRICK, H., STIMMLER, L., HLAD, C. J., & ARAI, Y. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-10-1076 · Cited by 857 · cited 1×
“0b013e32835edb32 INTRODUCTION In healthy individuals, oral ingestion of nutrients promotes a greater insulin response than parenteral infusion of an equivalent glucose load [1].”
BackgroundGöke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837
Nyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 2×
“However, these observations have not been replicated in primates or humans and are thought to be a rodent phenomenon because of the higher density of GLP-1Rs on rodent C-cells [50,51].”
BackgroundFarilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2003-0323 · Cited by 664 · cited 1×
“In preclinical studies, GLP-1 has been shown to protect b-cells [5].”
BackgroundBuse, J. B., Nauck, M., Forst, T., Sheu, W. H.-H., Shenouda, S. K., Heilmann, C. R., Hoogwerf, B. J., Gao, A., Boardman, M. K., Fineman, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61267-7 · Cited by 565
Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes
Noel, R. A., Braun, D. K., Patterson, R. E., & Bloomgren, G. L. (2009) · Diabetes Care · doi:10.2337/dc08-1755 · Cited by 435
Russell-Jones, D., Cuddihy, R. M., Hanefeld, M., Kumar, A., González, J. G., Chan, M., Wolka, A. M., Boardman, M. K., & on behalf of the DURATION-4 Study Group (2012) · Diabetes Care · doi:10.2337/dc11-1107 · Cited by 339
Identification and Actions of Gastric Inhibitory Polypeptide
BROWN, J. C., DRYBURGH, J. R., ROSS, S. A., & DUPRÉ, J. (1975) · Proceedings of the 1974 Laurentian Hormone Conference · doi:10.1016/b978-0-12-571131-9.50017-7 · Cited by 333
Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin
Garg, R., Chen, W., & Pendergrass, M. (2010) · Diabetes Care · doi:10.2337/dc10-0482 · Cited by 322
Nauck, M. A. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.002 · Cited by 295
Pratley, R., Nauck, M., Bailey, T., Montanya, E., Cuddihy, R., Filetti, S., Garber, A., Thomsen, A. B., Hartvig, H., Davies, M., et al. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02656.x · Cited by 253
Self-citationDeYoung, M. B., MacConell, L., Sarin, V., Trautmann, M., & Herbert, P. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0050 · Cited by 241
Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy
Fonseca, V. A., Alvarado-Ruiz, R., Raccah, D., Boka, G., Miossec, P., Gerich, J. E., & on behalf of the EFC6018 GetGoal-Mono Study Investigators (2012) · Diabetes Care · doi:10.2337/dc11-1935 · Cited by 218
Matthews, J. E., Stewart, M. W., De Boever, E. H., Dobbins, R. L., Hodge, R. J., Walker, S. E., Holland, M. C., Bush, M. A., & for the Albiglutide Study Group (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1518 · Cited by 198
Garber, A., Henry, R. R., Ratner, R., Hale, P., Chang, C. T., & Bode, B. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01356.x · Cited by 196
Self-citationHegedüs, L., Moses, A. C., Zdravkovic, M., Le Thi, T., & Daniels, G. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2318 · Cited by 194 · cited 2×
“However, these observations have not been replicated in primates or humans and are thought to be a rodent phenomenon because of the higher density of GLP-1Rs on rodent C-cells [50,51].”
BackgroundDeVries, J. H., Bain, S. C., Rodbard, H. W., Seufert, J., D’Alessio, D., Thomsen, A. B., Zychma, M., Rosenstock, J., & on behalf of the Liraglutide-Detemir Study Group (2012) · Diabetes Care · doi:10.2337/dc11-1928 · Cited by 159
Ratner, R. E., Rosenstock, J., Boka, G., & on behalf of the DRI6012 Study Investigators (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03020.x · Cited by 155
Buse, J. B., Garber, A., Rosenstock, J., Schmidt, W. E., Brett, J. H., Videbæk, N., Holst, J., & Nauck, M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2822 · Cited by 154
Self-citationRatner, R., Han, J., Nicewarner, D., Yushmanova, I., Hoogwerf, B. J., & Shen, L. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-22 · Cited by 153
A cohort study of acute pancreatitis in relation to exenatide use
Dore, D. D., Bloomgren, G. L., Wenten, M., Hoffman, C., Clifford, C. R., Quinn, S. G., Braun, D. K., Noel, R. A., & Seeger, J. D. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01376.x · Cited by 144
Marso, S. P., Lindsey, J. B., Stolker, J. M., House, J. A., Martinez Ravn, G., Kennedy, K. F., Jensen, T. M., & Buse, J. B. (2011) · Diabetes and Vascular Disease Research · doi:10.1177/1479164111408937 · Cited by 103
Grunberger, G., Chang, A., Garcia Soria, G., Botros, F. T., Bsharat, R., & Milicevic, Z. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03745.x · Cited by 102
Diamant, M., Van Gaal, L., Stranks, S., Guerci, B., MacConell, L., Haber, H., Scism-Bacon, J., & Trautmann, M. (2012) · Diabetes Care · doi:10.2337/dc11-1233 · Cited by 96
Thong, K. Y., Jose, B., Sukumar, N., Cull, M. L., Mills, A. P., Sathyapalan, T., Shafiq, W., Rigby, A. S., Walton, C., Ryder, R. E. J., et al. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01393.x · Cited by 96
Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.
Christensen, M., Knop, F. K., Holst, J. J., & Vilsbøll, T. (2009) · PubMed · Cited by 84
Wenten, M., Gaebler, J. A., Hussein, M., Pelletier, E. M., Smith, D. B., Girase, P., Noel, R. A., Braun, D. K., & Bloomgren, G. L. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03652.x · Cited by 75
Combining GLP ‐1 receptor agonists with insulin: therapeutic rationales and clinical findings
Holst, J. J., & Vilsbøll, T. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01628.x · Cited by 63
Davies, M., Pratley, R., Hammer, M., Thomsen, A. B., & Cuddihy, R. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03074.x · Cited by 60
How Does Treatment Satisfaction Work?
Peyrot, M., & Rubin, R. R. (2009) · Diabetes Care · doi:10.2337/dc08-2256 · Cited by 56
Chatterjee, D. J., Khutoryansky, N., Zdravkovic, M., Sprenger, C. R., & Litwin, J. S. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009339189 · Cited by 54
Davies, M., & Speight, J. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01595.x · Cited by 54
Forst, T., Weber, M. M., & Pfützner, A. (2012) · Experimental Diabetes Research · doi:10.1155/2012/635472 · Cited by 44 · cited 1×
“Unau Health | Lippincott Williams & Wilki risk factors such as weight, systolic blood pressure, and lipid profile [8].”
BackgroundA comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes
Montanya, E. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.692777 · Cited by 27
GLP-1 receptor agonists today.
Marre, M., & Penfornis, A. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.01.004 · Cited by 26
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463
Oxidative and endoplasmic reticulum stress in β-cell dysfunction in diabetes
Hasnain, S. Z., Prins, J. B., & McGuckin, M. A. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-15-0232 · Cited by 253
Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
Van Gaal, L., & Scheen, A. (2015) · Diabetes Care · doi:10.2337/dc14-1630 · Cited by 221
Zhang, Y., Parajuli, K. R., Fava, G. E., Gupta, R., Xu, W., Nguyen, L. U., Zakaria, A. F., Fonseca, V. A., Wang, H., Mauvais-Jarvis, F., et al. (2019) · Diabetes · doi:10.2337/db18-0317 · Cited by 104
Metadata
- Authors
- Samson, S. L., & Garber, A.
- Affiliations
- Baylor College of Medicine (US)
- Corresponding author
- Samson, Susan L.
- ORCID
- Samson, Susan L.
- Venue
- Current Opinion in Endocrinology, Diabetes & Obesity
- Published
- 2013-04
- Volume
- 20
- Issue
- 2
- Pages
- 87-97
- ISSN
- 1752-296X (ISSN-L)
- OpenAlex
- W2123127609
- Cited by
- 55
- References
- 42
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 2 · 2023: 4 · 2022: 5 · 2021: 2 · 2020: 4 · 2019: 5 · 2018: 2 · 2017: 3 · 2016: 4 · 2015: 9 · 2014: 9 · 2013: 3
- FWCI
- 1.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Endocrinology Diabetes and Obesity (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Intarcia Therapeutics
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK079638)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, glycemic control, weight loss, hypoglycemia risk, pancreatitis risk, thyroid cancer risk, cardiovascular safety, drug safety
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Liraglutide, Exenatide, Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Glucagon-Like Peptides, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Insulin, Male, Pancreatitis, Peptides, Recombinant Fusion Proteins, Thyroid Neoplasms, Venoms, Randomized Controlled Trials as Topic, Treatment Outcome, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.